Physician profile
William B Young
NPI 1841213477
$108,971.03
in general payments reported to CMS, 2019-2025
27 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $31K · 2021: $527 · 2022: $2,172 · 2023: $4,106 · 2024: $7,789 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,500 · Food and Beverage: $7,297 · Travel and Lodging: $3,944 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Honoraria: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,500.00 |
| Food and Beverage | $7,296.91 |
| Travel and Lodging | $3,944.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Honoraria | $1,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33,253.06 | 2019-2024 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $25,212.83 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Allergan, INC. | $22,938.03 | 2019-2022 | |
| Pfizer INC. | $11,152.65 | 2023-2025 | |
| Abbvie INC. | $6,179.02 | 2022-2025 | Ubrelvy, Botox, Qulipta |
| Impel Pharmaceuticals LLC | $4,795.83 | 2024-2025 | Trudhesa, Trudhesa |
| Tonix Medicines, INC. | $1,734.76 | 2023-2024 | Zembrace Symtouch |
| Amgen INC. | $778.24 | 2019-2024 | Aimovig |
| Impel Pharmaceuticals INC. | $503.63 | 2022-2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $486.96 | 2019-2020 | |
| Lundbeck LLC | $384.59 | 2021-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company Ltd. | $286.83 | 2022 | |
| Eli Lilly and Company | $212.82 | 2019-2024 | Emgality |
| Biohaven Pharmaceuticals, INC. | $181.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $148.49 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $145.58 | 2024-2025 | Symbravo |
| Upsher-Smith Laboratories LLC | $114.12 | 2019-2023 | |
| Avid Radiopharmaceuticals, INC. | $100.14 | 2024 | |
| Amneal Pharmaceuticals LLC | $99.17 | 2019-2024 | Zomig |
| Promius Pharma LLC | $61.99 | 2019 | |
| Assertio Therapeutics, INC. | $59.31 | 2019 | |
| Avanir Pharmaceuticals, INC. | $41.10 | 2019 | |
| Zyla Life Sciences, INC. | $28.66 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $23.37 | 2022 | |
| Eisai INC. | $18.81 | 2023 | |
| Collegium Pharmaceutical, INC. | $15.74 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.39 | 2024 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.